Ashley M Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley M Smith has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- David Arnott
Genentech, Inc., 1 DNA Way, MS63, South San Francisco, CA, 94080, USA.
1 shared publication - Joshua Haznedar
Department of PKPD within Development Sciences, Genentech, Inc. (a member of the Roche Group), 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Kristin R. Wildsmith
Division of Development Sciences, Department of OMNI Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Lee A. Honigberg
Development Sciences, Genentech Research and Early Development, South San Francisco, USA
1 shared publication - Stephen P. Schauer
Division of Development Sciences, Department of OMNI Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Surinder Kaur
Genentech, Inc., South San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 9 (1) , 22
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Alzheimer’s disease (AD) is the leading cause of dementia affecting greater than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ42, tau, and p-tau181 are well established as diagnostic biomarkers of AD, there is a need for additional CSF biomarkers of neuronal function that continue to change during disease progression and could be used as pharmacodynamic measures in clinical trials. Multiple proteomic discovery experiments have reported a range of CSF biomarkers that differ between AD and control subjects. These potential biomarkers represent multiple aspects of the disease pathology. The performance of these markers has not been compared with each other, and their performance has not been evaluated longitudinally.
- 1 January 2014
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 9 (1) , 22
Open AccessIdentification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Alzheimer’s disease (AD) is the leading cause of dementia affecting greater than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ42, tau, and p-tau181 are well established as diagnostic biomarkers of AD, there is a need for additional CSF biomarkers of neuronal function that continue to change during disease progression and could be used as pharmacodynamic measures in clinical trials. Multiple proteomic discovery experiments have reported a range of CSF biomarkers that differ between AD and control subjects. These potential biomarkers represent multiple aspects of the disease pathology. The performance of these markers has not been compared with each other, and their performance has not been evaluated longitudinally.